相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

在MAFLD中,肝动脉增强速度指数和肥胖症/纤维化

Hüseyin Gökhan Yavaş¹, Emre Emekli², Mehmet Korkmaz³

¹Department of Radiology, Kütahya Health Sciences University, Kutahya, Turkey. huseyingokhan.yavas@ksbu.edu.tr.

Abdominal radiology (New York)

|October 5, 2025

概括

肝动脉增强速度指数 (HAVI) 与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 中肝硬化症的严重程度相关. 这种多普勒超声波参数可能有助于非侵入性评估肝脏变化.

科学领域:

肝病学肝病学是一种肝病学.
医疗成像医学成像
血管超声波是指血管超声波.

背景情况:

与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 是慢性肝病的普遍原因.
准确的非侵入性评估肝硬化和纤维化对于管理MAFLD至关重要.
多普勒超声波参数为非侵入性肝脏评估提供了潜力.

研究的目的:

调查肝动脉增强速度指数 (HAVI) 与MAFLD患者肝硬化和纤维化严重程度之间的关联.
为了比较HAVI与肝动脉电阻指数 (HARI) 在评估肝病严重程度方面的实用性.
探索HAVI与已确定的非侵入性纤维化标志物的相关性.

主要方法:

对197名MAFLD患者进行了肝胆超声波,剪切波弹性图 (SWE) 和多普勒超声波的回顾性分析.
使用多普勒参数计算肝动脉电阻指数 (HARI) 和肝动脉增强速度指数 (HAVI).
肝硬度 (kPa),FIB-4评分和生物化学标志物在不同程度的肝肥胖症的比较.

主要成果:

随着肝肥胖症严重程度的增加,HAVI值显著增加 (p<0.01).
HAVI与肝硬度 (kPa) 呈现强烈的正相关性 (r=0.66,p<0.01) 以及与ALT,AST和GGT的中等相关性.
在HARI和肥胖症严重程度或纤维化标志物之间没有发现显著的关联.

结论:

在MAFLD患者中,HAVI显示了与肝硬化症严重程度和非侵入性纤维化标志物的显著关联.
在这个群体中,HARI没有显示出类似的关联.
HAVI需要进一步研究作为一种潜在的非侵入性多普勒衍生生物标志物,用于评估MAFLD中的肝脏辅酶和微血管变化.

关键词:

颜色颜色颜色颜色在多普勒测试中,多普勒弹性成像技术弹性成像技术脂肪肝是一种脂肪肝.纤维化纤维化纤维化超声波学超声波学超声波学

更多相关视频

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...